TScan doses first patient in Phase 3 heme trial, cites Cohort C manufacturing data
TScan Therapeutics reports first patient dosed in the ALLOHA-2 Phase 3 trial and shares Cohort C data supporting its commercial-ready manufacturing process, with cash into Q2 2027.
TScan Therapeutics announced in July that it had dosed the first patient in the ongoing Phase 3 ALLOHA-2 clinical trial evaluating TSC-101 for patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation.1 The company expects to complete enrollment and report topline data from this pivotal study in mid-2028.1
In June, TScan disclosed results from Cohort C of its Phase 1 "ALLOHA" study, registered as NCT05473910. The commercial-ready manufacturing process achieved roughly a 90% first-pass success rate, with 17 of 19 attempts succeeding.1 Most Cohort C patients had poor prognostic features going in, with 12 of 14, or 86%, testing positive for minimal residual disease before transplant, and the same proportion showing mixed donor chimerism at their first post-transplant assessment.1 Following TSC-101 infusion, 11 of 14 patients, or 79%, reached complete donor chimerism within about three weeks, and two more showed improving chimerism, a pattern the company links to clearing residual cancer cells and lowering relapse risk.1 Safety findings remained consistent with typical post-transplant adverse events.1
On manufacturing scale-up, TScan entered an agreement with Cellares in June to evaluate the company's automated Cell Shuttle and Cell Q platforms as a possible route to scalable, cost-efficient commercial production.1 Looking ahead, the company plans to start Phase 1 studies of TSC-102-A01 and TSC-102-A03 in the fourth quarter of 2026, with initial data expected in 2027.1
On finances, cash and cash equivalents stood at $100.2 million as of June 30, 2026, excluding $5.0 million in restricted cash.1 TScan said this funds its current operating plan into the second quarter of 2027.1 The company noted that it missed certain non-covenant milestones tied to its debt agreement by the June 30 deadline, which means the two-year term loan amortization under that agreement will begin in the fourth quarter of 2026, a factor reflected in the updated runway estimate.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.